Cipla Licenses Rifaximin Drugs To Salix Outside Of Asia, Africa
This article was originally published in PharmAsia News
Executive Summary
Cipla said it has sold a near-global license to Salix Pharmaceuticals for rifaximin complex-based antibiotics for which the India drug maker holds patents.